Principal Financial Group Inc. boosted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 2.3% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 77,679 shares of the company’s stock after purchasing an additional 1,728 shares during the period. Principal Financial Group Inc. owned about 0.09% of Neurocrine Biosciences worth $3,574,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of the stock. Teacher Retirement System of Texas grew its holdings in Neurocrine Biosciences by 0.8% during the 2nd quarter. Teacher Retirement System of Texas now owns 6,966 shares of the company’s stock valued at $320,000 after purchasing an additional 57 shares during the last quarter. Utah Retirement Systems grew its holdings in Neurocrine Biosciences by 1.9% during the 2nd quarter. Utah Retirement Systems now owns 16,000 shares of the company’s stock valued at $736,000 after purchasing an additional 300 shares during the last quarter. Schroder Investment Management Group grew its holdings in Neurocrine Biosciences by 1.7% during the 1st quarter. Schroder Investment Management Group now owns 20,496 shares of the company’s stock valued at $856,000 after purchasing an additional 335 shares during the last quarter. Nuveen Asset Management LLC grew its holdings in Neurocrine Biosciences by 5.6% during the 1st quarter. Nuveen Asset Management LLC now owns 14,464 shares of the company’s stock valued at $626,000 after purchasing an additional 763 shares during the last quarter. Finally, Aperio Group LLC grew its holdings in Neurocrine Biosciences by 3.7% during the 2nd quarter. Aperio Group LLC now owns 22,324 shares of the company’s stock valued at $1,027,000 after purchasing an additional 789 shares during the last quarter.

In related news, insider Haig P. Bozigian sold 22,500 shares of Neurocrine Biosciences stock in a transaction that occurred on Friday, August 4th. The shares were sold at an average price of $50.00, for a total value of $1,125,000.00. Following the completion of the transaction, the insider now owns 154,601 shares in the company, valued at $7,730,050. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Christopher Flint Obrien sold 52,817 shares of Neurocrine Biosciences stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $57.50, for a total transaction of $3,036,977.50. Following the completion of the transaction, the insider now owns 101,790 shares of the company’s stock, valued at approximately $5,852,925. The disclosure for this sale can be found here. Insiders sold 132,580 shares of company stock valued at $7,440,850 in the last 90 days. Company insiders own 4.80% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Principal Financial Group Inc. Has $3.57 Million Position in Neurocrine Biosciences, Inc. (NBIX)” was first reported by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another domain, it was stolen and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.watchlistnews.com/principal-financial-group-inc-has-3-57-million-position-in-neurocrine-biosciences-inc-nbix/1611728.html.

Neurocrine Biosciences, Inc. (NBIX) opened at 62.55 on Friday. Neurocrine Biosciences, Inc. has a 52 week low of $37.35 and a 52 week high of $63.77. The firm has a 50-day moving average of $56.92 and a 200-day moving average of $50.37. The company’s market capitalization is $5.52 billion.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings results on Thursday, August 3rd. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.01). The firm had revenue of $6.34 million for the quarter, compared to analyst estimates of $0.61 million. During the same quarter last year, the business earned ($0.46) earnings per share. Analysts anticipate that Neurocrine Biosciences, Inc. will post ($2.44) EPS for the current fiscal year.

NBIX has been the topic of several analyst reports. BidaskClub upgraded shares of Neurocrine Biosciences from a “sell” rating to a “hold” rating in a report on Wednesday, June 21st. Oppenheimer Holdings, Inc. reiterated an “outperform” rating and set a $70.00 price target on shares of Neurocrine Biosciences in a report on Wednesday, July 5th. BMO Capital Markets upped their price target on shares of Neurocrine Biosciences from $75.00 to $84.00 and gave the company an “outperform” rating in a report on Friday, August 4th. Cowen and Company reiterated an “outperform” rating and set a $65.00 price target (up from $60.00) on shares of Neurocrine Biosciences in a report on Wednesday, August 9th. Finally, Piper Jaffray Companies set a $68.00 price target on shares of Neurocrine Biosciences and gave the company a “buy” rating in a report on Thursday, August 24th. Two analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $68.44.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.